Public Sector Pension Investment Board Purchases Shares of 381,172 Sarepta Therapeutics, Inc. $SRPT

Public Sector Pension Investment Board acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 381,172 shares of the biotechnology company’s stock, valued at approximately $7,345,000. Public Sector Pension Investment Board owned about 0.39% of Sarepta Therapeutics as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in SRPT. Geode Capital Management LLC boosted its stake in Sarepta Therapeutics by 3.0% during the second quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock valued at $32,085,000 after buying an additional 55,076 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Sarepta Therapeutics by 347.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company’s stock valued at $22,370,000 after acquiring an additional 1,016,069 shares during the last quarter. Norges Bank purchased a new position in shares of Sarepta Therapeutics in the second quarter valued at $15,619,000. Y Intercept Hong Kong Ltd increased its position in Sarepta Therapeutics by 1,736.5% in the second quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company’s stock worth $14,880,000 after purchasing an additional 822,799 shares during the last quarter. Finally, 683 Capital Management LLC raised its stake in Sarepta Therapeutics by 309.1% during the second quarter. 683 Capital Management LLC now owns 675,000 shares of the biotechnology company’s stock valued at $11,542,000 after purchasing an additional 510,000 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. The trade was a 6.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.60% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on SRPT shares. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Bank of America lifted their price target on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a research report on Wednesday, October 22nd. Royal Bank Of Canada upped their price objective on Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research report on Thursday, January 8th. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a report on Tuesday, January 27th. Finally, Guggenheim decreased their price target on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $33.84.

Sarepta Therapeutics Price Performance

SRPT opened at $17.88 on Wednesday. The business has a fifty day moving average of $20.94 and a 200 day moving average of $20.20. The stock has a market cap of $1.87 billion, a P/E ratio of -5.94, a PEG ratio of 0.45 and a beta of 0.39. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $110.00.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.